Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Theragenics to test brachytherapy for restenosis:

This article was originally published in Clinica

Executive Summary

Theragenics has gained approval from the US FDA to begin a clinical trial of its palladium-103-based intravascular brachytherapy system for preventing restenosis. The TheraP trial is a nonrandomised study investigating the safety and feasibility of the Buford, Georgia firm's TheraSource system for preventing restenosis following balloon angioplasty. The study will include long diffuse lesions in the superficial femoral and popliteal arteries. Around 30 patients are expected to be enrolled at up to three sites.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts